KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Prenatal Intravenous Iron and Child Growth: A Secondary Analysis of a Randomized Clinical Trial.

Glory Mzembe, William Nkhono, Ernest Moya, Rebecca Harding, Justina Kaunda, Alex Thawani, Mphatso Mwambinga, Owen Mtambo, Zinenani Truwah, Maclean Vokhiwa, Gomezgani Mhango, Ayse Y Demir, Hans Verhoef, Ricardo Ataíde, Sabine Braat, Sant-Rayn Pasricha, Kamija S Phiri, Martin N Mwangi

JAMA Netw Open 8(10) e2538392

PMID41148141
PMCIDPMC12569709
DOI10.1001/jamanetworkopen.2025.38392
发表日期2025-10-28
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other。
摘要

摘要

IMPORTANCE: Maternal anemia during pregnancy is associated with poor growth during early childhood, but it remains unclear whether treatment using intravenous iron could enhance child growth. OBJECTIVE: To evaluate whether intravenous ferric carboxymaltose (FCM) treatment for moderate to severe anemia during the second trimester of pregnancy enhances postnatal child growth compared with standard-of-care (SOC) oral iron. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of a randomized clinical trial (Randomized Controlled Trial of the Effect of Intravenous Iron on Anaemia in Malawian Pregnant Women [REVAMP]). In REVAMP, pregnant women with capillary hemoglobin between 5 and 10 g/dL were recruited in the Blantyre and Zomba districts of southern Malawi between November 2018 and March 2022 and randomized to FCM or SOC. Their infants were followed up over 12 months post partum. Data analysis was conducted between August 2024 and August 2025. INTERVENTION: Mothers were given intravenous FCM up to 1000 mg once on trial enrollment (intervention group) or SOC oral ferrous sulfate, 200 mg twice daily (approximately 120 mg elemental iron per day) (control group) from 13 to 26 weeks' gestation until delivery. Children received no intervention. MAIN OUTCOMES AND MEASURES: Length-for-age z score (LAZ) at 12 months was the primary growth outcome; secondary outcomes included weight-for-age z scores (WAZ), weight-for-length z scores (WLZ), stunting (LAZ <-2), underweight (WAZ <-2), and wasting (WLZ <-2). Length and weight were measured at birth and at 1, 3, 6, 9, and 12 months post partum. The repeated measures were analyzed using mixed-effects models. RESULTS: A total of 738 infants were followed up for 12 months between March 2019 and October 2022. A total of 371 (193 [52.0%] male; mean [SD] gestational age at birth, 39.5 [1.9] weeks) were in the FCM group, and 367 (187 [51.2%] male; mean [SD] gestational age at birth, 39.4 [2.3] weeks) were in the SOC group. There was no evidence of a difference between FCM and SOC groups in mean LAZ (mean difference, -0.15 [95% CI, -0.37 to 0.08]), WAZ (mean difference, -0.02 [95% CI, -0.21 to 0.16]) or WLZ (mean difference, 0.02 [95% CI, -0.20 to 0.24]) at 12 months. Similarly, there was no difference in the proportion with stunting, underweight, or wasting at all time points. Stunting was more common in mothers younger than 20 years, less than 150 cm in height, and with no education or primary education only, although treatment effects showed no evidence of heterogeneity. CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial in southern Malawi, intravenous FCM treatment for moderate to severe anemia during the second trimester of pregnancy was not associated with substantial benefits on infant growth compared with SOC. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12618001268235.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Study Flow Diagram Missing data were mainly due to the COVID-19 pandemic and lockdowns, which affected participants attendance of the study visits. Additionally, for 1-month and 3-month visits, delays in ethics approval to extend the trial follow-up and add infant growth as one of the secondary objectives of the trial meant some participants were systematically missed. These participants were already older than 3 months when they were reconsented for the extended follow-up. FCM indicates ferric carboxymaltose; SOC, standard of care. a A total of 5 infants were excluded because they did not have growth data at any time point. b A total of 12 infants were excluded because they did not have growth data at any time point.
非 KM Figure
Figure 2Figure 2.. Mean z Scores and Proportions With Stunting, Underweight, and Wasting LAZ indicates length for age z score; FCM, ferric carboxymaltose; SOC, standard of care; WAZ, weight-for-age z score; WLZ, weight-for-length z score.
非 KM Figure